AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11591569 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium bromide CFC, 42 microg
Number of subjects: 507
Study 9853278 — intervention group
Group type: COMPARATOR
Intervention: Conventional system
Number of subjects: 147
Study 9853278 — intervention group
Group type: COMPARATOR
Intervention: Y-set system
Number of subjects: 147
Study 9853278 — intervention group
Group type: COMPARATOR
Intervention: Twin bag system
Number of subjects: 147
Study 7989278 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine
Number of subjects: 32
Study 7989278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2919131 — intervention group
Group type: EXPERIMENTAL
Intervention: 15N glycine
Number of subjects: 11
Study 2919131 — intervention group
Group type: EXPERIMENTAL
Intervention: 15N yeast protein hydrolysate
Number of subjects: 11
Study 2919131 — intervention group
Group type: COMPARATOR
Intervention: Low birth weight formula
Number of subjects: 11
Study 2919131 — intervention group
Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 11
Study 31247132 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD capsules administered with food (high fat 840‐860 calorie)
Number of subjects: 8
Study 31247132 — intervention group
Group type: COMPARATOR
Intervention: CBD capsules administered without food (fasting)
Number of subjects: 8
Study 29254862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam (2000 mg ceftazidime and 500 mg avibactam by 2 h intravenous infusion every 8 h for 7-14 days)
Number of subjects: 879
Study 29254862 — intervention group
Group type: COMPARATOR
Intervention: Meropenem (1000 mg by 30-min intravenous infusion every 8 h for 7-14 days)
Number of subjects: 879
Study 29254862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Number of subjects: 879
Study 29254862 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 879
Study 27159846 — intervention group
Group type: EXPERIMENTAL
Intervention: Retro-chop nucleotomy
Number of subjects: 111
Study 27159846 — intervention group
Group type: COMPARATOR
Intervention: Stop-chop nucleotomy
Number of subjects: 111
Study 27159846 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 111
Study 23748855 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker diabetes education/case management (7 hours)
Number of subjects: 16
Study 23748855 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual medical care)
Number of subjects: 16
Study 22648717 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (300 mg/d)
Number of subjects: 44
Study 22648717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 20614483 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM)
Number of subjects: 90
Study 20614483 — intervention group
Group type: COMPARATOR
Intervention: Endorectal advancement flap (ERAF)
Number of subjects: 90
Study 16538700 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical model
Number of subjects: 0
Study 16538700 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-level methods
Number of subjects: 0
Study 16538700 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-level summary measures
Number of subjects: 0
Study 16538700 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical modelling
Number of subjects: 0
Study 15630387 — intervention group
Group type: EXPERIMENTAL
Intervention: Telescopic-assisted adenoidectomy using radiofrequency curette
Number of subjects: 120
Study 15630387 — intervention group
Group type: COMPARATOR
Intervention: Conventional adenoid-curette adenoidectomy
Number of subjects: 120
Study 14703896 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (Tensiomin)
Number of subjects: 14
Study 14703896 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium dimercaptosulphonate (DMPS)
Number of subjects: 14
Study 14703896 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drug)
Number of subjects: 14
Study 10885048 — intervention group
Group type: EXPERIMENTAL
Intervention: Puppet condition (P)
Number of subjects: 395
Study 10885048 — intervention group
Group type: COMPARATOR
Intervention: Unbiased questionnaire without puppet reference (Q)
Number of subjects: 395
Study 10885048 — intervention group
Group type: EXPERIMENTAL
Intervention: Puppet method (P) after 1 month
Number of subjects: 395
Study 10885048 — intervention group
Group type: COMPARATOR
Intervention: Unbiased questionnaire (Q) after 1 month
Number of subjects: 395
Study 8895046 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine monotherapy
Number of subjects: 115
Study 8895046 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine combined with ketamine and lignocaine
Number of subjects: 115
Study 1671993 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol with continuous application of an eyepad
Number of subjects: 30
Study 1671993 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol without the eyepad
Number of subjects: 30
Study 6839761 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu-22OC
Number of subjects: 1199
Study 6839761 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiload Cu250
Number of subjects: 1199
Study 6839761 — intervention group
Group type: COMPARATOR
Intervention: Cu7
Number of subjects: 1199
Study 30414998 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed suture (V‐Loc 90; Medtronic/Covidien)
Number of subjects: 150
Study 30414998 — intervention group
Group type: COMPARATOR
Intervention: Polyglactin 910 (coated Vicryl suture; Ethicon/Johnson & Johnson)
Number of subjects: 150
Study 28342990 — intervention group
Group type: EXPERIMENTAL
Intervention: telephone-adapted Mindfulness-based Stress Reduction (tMBSR), an 8-week program of meditation and yoga
Number of subjects: 63
Study 28342990 — intervention group
Group type: COMPARATOR
Intervention: telephone-based support group (tSupport)
Number of subjects: 63
Study 28342990 — intervention group
Group type: EXPERIMENTAL
Intervention: tMBSR
Number of subjects: 63
Study 28342990 — intervention group
Group type: COMPARATOR
Intervention: tSupport
Number of subjects: 63
Study 27178865 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitatory anodal tDCS (a‐tDCS)
Number of subjects: 26
Study 27178865 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (s‐tDCS)
Number of subjects: 26
Study 24430578 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene mesh fixed with polypropylene sutures (group A)
Number of subjects: 50
Study 24430578 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-fixating polypropylene mesh with resorbable polylactic acid microgrips (group B)
Number of subjects: 50
Study 24430578 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study 22770932 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation (2 * 15 g, twice daily)
Number of subjects: 62
Study 22770932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 22770932 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Protein and Placebo)
Number of subjects: 62
Study 19509020 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cortisol infusion (physiologic levels during hypoglycemia)
Number of subjects: 22
Study 19509020 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cortisol infusion (twofold greater elevations of plasma cortisol)
Number of subjects: 22
Study 19509020 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemic clamps (2.9 mmol/l)
Number of subjects: 22
Study 19509020 — intervention group
Group type: COMPARATOR
Intervention: Euglycemic clamps (5.1 mmol/l)
Number of subjects: 22
Study 17244352 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for 2 years
Number of subjects: 677
Study 17244352 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for 5 years
Number of subjects: 677
Study 17244352 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for 5 years (multivariate Cox model)
Number of subjects: 677
Study 17244352 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (general)
Number of subjects: 677
Study 15998903 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg daily)
Number of subjects: 124
Study 15998903 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg daily)
Number of subjects: 124
Study 15998903 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tamoxifen and anastrozole
Number of subjects: 124
Study 15998903 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 124
Study 15998903 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 124
Study 15998903 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 124
Study 11928797 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical and chemotherapeutic treatment
Number of subjects: 0
Study 10093945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (10 mg/kg/day in two divided doses for 5 days)
Number of subjects: 82
Study 10093945 — intervention group
Group type: COMPARATOR
Intervention: Cefixime (20 mg/kg/day in two divided doses for 7 days)
Number of subjects: 82
Study 7486178 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (0.15, 0.45, 1.5 ppm)
Number of subjects: 6
Study 7486178 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous almitrine (16 micrograms.kg-1.min-1)
Number of subjects: 6
Study 7486178 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine plus inhaled nitric oxide (1.5 ppm)
Number of subjects: 6
Study 2030370 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day tetrahydroaminoacridine (THA) and 10 g/day lecithin
Number of subjects: 12
Study 2030370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7044195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocortin butylester (FCB) 4 mg
Number of subjects: 50
Study 7044195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31600428 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium phosphite (PP) + Water Deficit (WD)
Number of subjects: 5
Study 31600428 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen sulphide (HS) + Water Deficit (WD)
Number of subjects: 5
Study 31600428 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate (ZS) + Water Deficit (WD)
Number of subjects: 5
Study 31600428 — intervention group
Group type: COMPARATOR
Intervention: Well-watered control (WW)
Number of subjects: 5
Study 31600428 — intervention group
Group type: COMPARATOR
Intervention: Water Deficit (WD)
Number of subjects: 5
Study 31846014 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (1.2 mg/kg)
Number of subjects: 1248
Study 31846014 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine (1 mg/kg)
Number of subjects: 1248
Study 28705122 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application with active reminders of oral hygiene (3 times a day)
Number of subjects: 44
Study 28705122 — intervention group
Group type: COMPARATOR
Intervention: Verbal oral hygiene instructions
Number of subjects: 44
Study 26972780 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC
Number of subjects: 63
Study 26972780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 26972780 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TDF/FTC and Placebo)
Number of subjects: 63
Study 22672441 — intervention group
Group type: EXPERIMENTAL
Intervention: ePsychNurse.Net
Number of subjects: 137
Study 22672441 — intervention group
Group type: COMPARATOR
Intervention: Training as usual (Control)
Number of subjects: 137
Study 21396307 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-enriched TPN
Number of subjects: 50
Study 21396307 — intervention group
Group type: COMPARATOR
Intervention: Standard TPN
Number of subjects: 50
Study 18438249 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate plyometric training (2 days per week, 840 DJs)
Number of subjects: 42
Study 18438249 — intervention group
Group type: EXPERIMENTAL
Intervention: Low plyometric training (1 day per week, 420 DJs)
Number of subjects: 42
Study 18438249 — intervention group
Group type: EXPERIMENTAL
Intervention: High plyometric training (4 days per week, 1680 DJs)
Number of subjects: 42
Study 18438249 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10, 7 sessions of drop jump training, 1 day per week, 420 DJs)
Number of subjects: 42
Study 16550733 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg b.i.d. for 7 days plus norethisterone and ethinyl estradiol on Day 7
Number of subjects: 20
Study 16550733 — intervention group
Group type: COMPARATOR
Intervention: OrthoNovum containing 1 mg norethisterone and 35 microg ethinyl estradiol
Number of subjects: 20
Study 12687508 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program (SMP) consisting of 3 group sessions and telephone follow-up.
Number of subjects: 211
Study 12687508 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 211
Study 10880410 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg per day)
Number of subjects: 3090
Study 10880410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3090
Study 9234037 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (15 mg/70 kg)
Number of subjects: 13
Study 9234037 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (30 mg/70 kg)
Number of subjects: 13
Study 9234037 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.75 mg/70 kg)
Number of subjects: 13
Study 9234037 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1.5 mg/70 kg)
Number of subjects: 13
Study 9234037 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (15 mg/70 kg) + Ethanol (0‐0.6 g/kg)
Number of subjects: 13
Study 9234037 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (30 mg/70 kg) + Ethanol (0‐0.6 g/kg)
Number of subjects: 13
Study 9234037 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.75 mg/70 kg) + Ethanol (0‐0.6 g/kg)
Number of subjects: 13
Study 9234037 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1.5 mg/70 kg) + Ethanol (0‐0.6 g/kg)
Number of subjects: 13
Study 9234037 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (0‐0.6 g/kg)
Number of subjects: 13
Study 9234037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 1407749 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 0
Study 1407749 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 0
Study 1407749 — intervention group
Group type: COMPARATOR
Intervention: Control group (no coffee consumption)
Number of subjects: 0
Study 3980799 — intervention group
Group type: EXPERIMENTAL
Intervention: Suberythemogenic doses of ultraviolet B (UVB) radiation with tar oil
Number of subjects: 49
Study 3980799 — intervention group
Group type: COMPARATOR
Intervention: Maximally erythemogenic UVB radiation with emollients
Number of subjects: 49
Study 30558284 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted serum 25-hydroxyvitamin D concentrations
Number of subjects: 173005
Study 26990315 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative synbiotics
Number of subjects: 44
Study 26990315 — intervention group
Group type: COMPARATOR
Intervention: No synbiotics (control group)
Number of subjects: 44
Study 24445084 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill-based supervised exercise training (SET) alone for 12 weeks
Number of subjects: 35
Study 24445084 — intervention group
Group type: COMPARATOR
Intervention: Treadmill-based supervised exercise training (SET) combined with resistance training for 12 weeks
Number of subjects: 35
Study 22150712 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 motivational SMSs (MOTI)
Number of subjects: 2533
Study 22150712 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 motivational SMSs (MOTI)
Number of subjects: 2533
Study 22150712 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 informational SMSs (INFO)
Number of subjects: 2533
Study 22150712 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 informational SMSs (INFO)
Number of subjects: 2533
Study 22150712 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2533
Study 20401689 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 148
Study 20401689 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 148
Study 18554874 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 10
Study 18554874 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 10
Study 18037257 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam body-support device
Number of subjects: 70
Study 18037257 — intervention group
Group type: COMPARATOR
Intervention: Standard pressure sore prevention protocol (Control)
Number of subjects: 70
Study 15586632 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuation corrected ECT values using the subtraction attenuation map
Number of subjects: 10
Study 15586632 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical evaluation of attenuation corrected ECT values
Number of subjects: 10
Study 15586632 — intervention group
Group type: COMPARATOR
Intervention: Non-corrected images
Number of subjects: 10
Study 11754126 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clomipramine (IV CMI) 25 mg increasing to 250 mg by day 10, continuing to day 14
Number of subjects: 44
Study 11754126 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clomipramine (IV CMI)
Number of subjects: 44
Study 9249234 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg mibefradil
Number of subjects: 239
Study 9249234 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg amlodipine
Number of subjects: 239
Study 9249234 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 239
Study 8514538 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ascorbic acid solution applied twice per day during radiotherapy
Number of subjects: 84
Study 8514538 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo) applied twice per day during radiotherapy
Number of subjects: 84
Study 2881130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin for 3 months followed by azathioprine and prednisone
Number of subjects: 72
Study 2881130 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine and prednisone from the day of transplantation (conventional group)
Number of subjects: 72
Study 30401559 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined obturator nerve block (ONB) and tibial nerve block (TNB) with continuous adductor canal block and local infiltration analgesia (LIA)
Number of subjects: 90
Study 30401559 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial nerve block (TNB) with continuous adductor canal block and local infiltration analgesia (LIA)
Number of subjects: 90
Study 30401559 — intervention group
Group type: COMPARATOR
Intervention: Obturator nerve block (ONB) with continuous adductor canal block and local infiltration analgesia (LIA)
Number of subjects: 90
Study 28704584 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of solifenacin 5 mg + mirabegron 25 mg
Number of subjects: 3527
Study 28704584 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of solifenacin 5 mg + mirabegron 50 mg
Number of subjects: 3527
Study 28704584 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin 5 mg
Number of subjects: 3527
Study 28704584 — intervention group
Group type: COMPARATOR
Intervention: Mirabegron 25 mg
Number of subjects: 3527
Study 28704584 — intervention group
Group type: COMPARATOR
Intervention: Mirabegron 50 mg
Number of subjects: 3527
Study 28704584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3527
Study 27688221 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention (Phases II and III)
Number of subjects: 965
Study 27688221 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based intervention (Phase I)
Number of subjects: 965
Study 27688221 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention
Number of subjects: 965
Study 25105475 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency ultrasound (HFUS) at 1 MHz, 0.5 W/cm2, duty cycle of 20%, 1-3 minutes/cm2; one session per day, 5 days a week, in addition to standard wound care (SWC)
Number of subjects: 42
Study 25105475 — intervention group
Group type: COMPARATOR
Intervention: Standard wound care (SWC) only
Number of subjects: 42
Study 22257975 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 30
Study 22257975 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 30
Study 22257975 — intervention group
Group type: COMPARATOR
Intervention: Baseline (untreated)
Number of subjects: 30
Study 22257975 — intervention group
Group type: COMPARATOR
Intervention: Comparison to healthy subjects
Number of subjects: 30
Study 19129157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention group (personal telephone calls)
Number of subjects: 1181
Study 19129157 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1181
Study 17989547 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydration with approximately 1 l fluid for minor surgical procedures; 1-3 l fluid for moderate surgical procedures (laparoscopic surgery)
Number of subjects: 0
Study 17989547 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of a carbohydrate-rich beverage preoperatively
Number of subjects: 0
Study 17989547 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 15891265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg) given twice daily for 14 days
Number of subjects: 10
Study 15891265 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine (150 mg) given twice daily for 14 days
Number of subjects: 10
Study 12489275 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Number of subjects: 0
Study 12489275 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy combined with fecal occult blood tests
Number of subjects: 0
Study 9797854 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyloestradiol (EE2)
Number of subjects: 32